Evidence map›Paper›PMID 41371259›Full record

ReviewThe Journal of international medical research2025

In and outside the spotlight: Nanomedicine in the treatment of osteoporosis.

Hao Qu, Wenkang Luan, Yu He, Ying Chen

Abstract readReview
In one paragraph

Review in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hao QuPlastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China.ORCID 0000-0003-1760-2254
Wenkang LuanPlastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China.ORCID 0000-0001-9922-3340
Yu HePlastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China.
Ying ChenPlastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis, a high-incidence chronic disease, is known to cause physical pain, even leading to disability of patients, and creates a vast social burden. To improve the shortcomings of the current clinical osteoporosis treatment drugs, several studies have designed a multitude of nanomedicines to optimize traditional drugs based on the TOP-DOWN design. Fascinating nanomedicine designs are breathing vitality into traditional osteoporosis drugs. However, considering the unique pathological characteristics of osteoporosis and clinical treatment needs, we should also pay attention to the problems outside the spotlight. Here, we reviewed the current clinical osteoporosis treatment drugs, summarized their limitations, and generalized the nanomedicines designed based on the TOP-DOWN strategy for the mentioned deficiencies. In addition, we explored the issues outside the spotlight of the nanomedicine design for the treatment of osteoporosis because of the gap between laboratory design strategy and clinical demands and then determined the rational design of nanomedicines for osteoporosis.

Indexed as

Bone Density Conservation AgentsNanomedicineOsteoporosisAnimalsHumansBone Density Conservation AgentsnanomedicineOsteoporosistraditional drug

Identifiers

PMID41371259
PMCPMC13213104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.